These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 25047250)

  • 1. Twice-daily pill could treat leukemia.
    Printz C
    Cancer; 2014 Aug; 120(15):2225. PubMed ID: 25047250
    [No Abstract]   [Full Text] [Related]  

  • 2. Idelalisib Bolsters CLL Regimen.
    Leslie M
    Cancer Discov; 2016 Mar; 6(3):OF2. PubMed ID: 26772993
    [No Abstract]   [Full Text] [Related]  

  • 3. Chemoimmunotherapy in chronic lymphocytic leukemia.
    Stilgenbauer S
    Clin Adv Hematol Oncol; 2010 Dec; 8(12):867-8. PubMed ID: 21326163
    [No Abstract]   [Full Text] [Related]  

  • 4. Rituximab-containing therapy for chronic lymphocytic leukaemia.
    Tanimoto T; Sakiyama M; Hori A; Yagasaki F; Kami M
    Lancet; 2011 Jan; 377(9761):205; author reply 206. PubMed ID: 21237394
    [No Abstract]   [Full Text] [Related]  

  • 5. Rituximab-containing therapy for chronic lymphocytic leukaemia.
    Haines I; Elliott P; Stanley R
    Lancet; 2011 Jan; 377(9761):205; author reply 206. PubMed ID: 21237393
    [No Abstract]   [Full Text] [Related]  

  • 6. Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment.
    Betrian S; Ysebaert L; Heider KH; Delord JP; Fournié JJ; Quillet-Mary A
    Blood Cancer J; 2016 Nov; 6(11):e496. PubMed ID: 27834943
    [No Abstract]   [Full Text] [Related]  

  • 7. CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia.
    Cramer P; von Tresckow J; Bahlo J; Engelke A; Langerbeins P; Fink AM; Fischer K; Wendtner CM; Kreuzer KA; Stilgenbauer S; Böttcher S; Eichhorst B; Hallek M
    Future Oncol; 2018 Mar; 14(6):499-513. PubMed ID: 29465308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and stem cell toxicity of cladribine and rituximab in the treatment of patients with chronic lymphocytic leukemia: are all purine analogs created equal?
    Tadmor T; Polliack A; Tam CS
    Leuk Lymphoma; 2010 Apr; 51(4):571-3. PubMed ID: 20141447
    [No Abstract]   [Full Text] [Related]  

  • 9. Idelalisib-related pneumonitis.
    Haustraete E; Obert J; Diab S; Abbes S; Zini JM; Valade S; Lerolle N; Albin N; Arnulf B; Bouaziz JD; Hussenet C; Tazi A; Bergeron A
    Eur Respir J; 2016 Apr; 47(4):1280-3. PubMed ID: 26917607
    [No Abstract]   [Full Text] [Related]  

  • 10. Idelalisib--a PI3Kδ inhibitor for B-cell cancers.
    Fruman DA; Cantley LC
    N Engl J Med; 2014 Mar; 370(11):1061-2. PubMed ID: 24620870
    [No Abstract]   [Full Text] [Related]  

  • 11. Obinutuzumab looks impressive in CLL.
    Cancer Discov; 2014 Apr; 4(4):OF5. PubMed ID: 24706674
    [No Abstract]   [Full Text] [Related]  

  • 12. Chemoimmunotherapy of chronic lymphocytic leukemia.
    Tam CS; Keating MJ
    Best Pract Res Clin Haematol; 2007 Sep; 20(3):479-98. PubMed ID: 17707835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic lymphocytic leukemia with nuclear budding.
    Huang JZ; Folbe MH; Richards SK; Kolins MD
    Eur J Haematol; 2012 Jan; 88(1):92. PubMed ID: 21801234
    [No Abstract]   [Full Text] [Related]  

  • 14. PI3K-δ inhibitor produces long-lasting responses.
    Cancer Discov; 2013 Jul; 3(7):OF11. PubMed ID: 23847354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current concepts in chronic lymphocytic leukemia. Better chances for young patients].
    Hallek M; Bergmann M; Goede V; Fingerle-Rowson G; Schweighofer C; Schmitt B; Wendtner CM; Emmerich B
    MMW Fortschr Med; 2003 Jul; 145(27-28):46-9. PubMed ID: 14587189
    [No Abstract]   [Full Text] [Related]  

  • 17. Monoclonal antibodies in chronic lymphocytic leukemia.
    Ferrajoli A; Faderl S; Keating MJ
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1231-8. PubMed ID: 17020457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment options for newly diagnosed patients with chronic lymphocytic leukemia.
    Erba HP
    Curr Hematol Rep; 2004 Jan; 3(1):47-53. PubMed ID: 14695850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agranulocytosis occurring in a patient with chronic lymphocytic leukemia in complete remission; treatment by rituximab and cyclosporin.
    Costello RT; Sébahoun G
    Leuk Res; 2010 Dec; 34(12):e329-30. PubMed ID: 20723978
    [No Abstract]   [Full Text] [Related]  

  • 20. [Specific palatal infiltration in B-cell chronic lymphocytic leukemia].
    Cervigón I; Palomo A; Torres-Iglesias LM; Solano F; Zapata AM
    Actas Dermosifiliogr; 2011 May; 102(4):305-7. PubMed ID: 21354544
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.